US 11,690,807 B2
Implantable device for sustained release of a macromolecular drug compound
Christian Schneider, Hattersheim (DE)
Assigned to Celanese EVA Performance Polymers LLC, Irving, TX (US)
Filed by Celanese EVA Performance Polymers LLC, Irving, TX (US)
Filed on May 20, 2019, as Appl. No. 16/416,325.
Claims priority of provisional application 62/675,982, filed on May 24, 2018.
Prior Publication US 2019/0358167 A1, Nov. 28, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/50 (2006.01); A61K 38/48 (2006.01); A61K 38/39 (2006.01)
CPC A61K 9/5073 (2013.01) [A61K 9/5026 (2013.01); A61K 9/5031 (2013.01); A61K 38/39 (2013.01); A61K 38/4873 (2013.01); C12Y 304/22004 (2013.01)] 32 Claims
 
1. An implantable device for delivery of a macromolecular drug compound, the device comprising:
a core having an outer surface, wherein the core comprises a core polymer matrix within which is dispersed a macromolecular drug compound having a molecular weight of about 5 kDa or more, the core polymer matrix containing a first ethylene vinyl acetate copolymer, the first ethylene vinyl acetate copolymer having a melt flow index of from about 10 to about 80 grams per 10 min as determined in accordance with ASTM D1238-13 at a temperature of 190° C. and a load of 2.16 kilograms polymer; and
a membrane layer positioned adjacent to the outer surface of the core, wherein the membrane layer comprises a membrane polymer matrix within which the macromolecular drug compound is optionally dispersed, wherein the concentration of the macromolecular drug compound in the core is greater than the concentration of the macromolecular drug compound in the membrane layer, the membrane polymer matrix comprising a second ethylene vinyl acetate copolymer having a melt flow index of from about 10 to about 80 grams per 10 min as determined in accordance with ASTM D1238-13 at a temperature of 190° C. and a load of 2.16 kilograms and a hydrophilic compound, wherein the second ethylene vinyl acetate copolymer constitutes from about 70 wt. % to about 99 wt. % of the membrane layer, and wherein the implantable device has a release rate between 0.1E+0 and 3.5E+2 μg per hour for a time period up to about 1500 hours.